From bench to bedside: Therapeutic potential of interleukin‑9 in the treatment of asthma (Review)
- Authors:
- Published online on: January 4, 2017 https://doi.org/10.3892/etm.2017.4024
- Pages: 389-394
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Initially identified as a T cell and mast cell growth factor, interleukin (IL)‑9 has long been recognized as an important mediator of asthma. Recently, accumulating results from transgenic mice demonstrated that systemic or lung‑specific overexpression of IL‑9 caused asthma‑associated symptoms. Moreover, anti‑mIL‑9 antibody (Ab) blocking treatment alleviated disease in animal models of asthma. In light of the large quantity of data from the murine models, MEDI‑528, a humanized anti‑IL‑9 monoclonal Ab has been produced to assess the activity of IL‑9 on human asthma. In order to ascertain whether it is a successful translation from bench to bedside, the biological features of IL‑9 were evaluated and up‑to‑date information regarding the role of IL‑9 in different experimental murine models and human asthma were summarized.
